2.
Clinical factors associated with EGFRvIII expression level by univariate analysis
| Clinical factors | EGFRvIII expression (%) | P | |
| Low expression | High expression | ||
| EGFRvIII, epidermal growth factor receptor variant III; KPS, Karnofsky performance scale; MGMT, O6-methylguanine-DNA methyltransferase; IDH, isocitrate dehydrogenase. | |||
| Gender | 0.318 | ||
| Male | 72.0 (103/143) | 28.0 (40/143) | |
| Female | 66.0 (64/97) | 34.0 (33/97) | |
| Age (year) | 0.001 | ||
| <50 | 75.3 (137/182) | 24.7 (45/182) | |
| ≥50 | 51.7 (30/58) | 48.3 (28/58) | |
| Tumor size (cm) | 0.888 | ||
| <6 | 69.2 (83/120) | 30.8 (37/120) | |
| ≥6 | 70.0 (84/120) | 30.0 (36/120) | |
| KPS score | 0.037 | ||
| ≤80 | 62.5 (65/104) | 37.5 (39/104) | |
| >80 | 75.0 (102/136) | 25.0 (34/136) | |
| Tumor grade | <0.001 | ||
| II | 88.1 (74/84) | 11.9 (10/84) | |
| III+IV | 59.6 (93/156) | 40.4 (63/156) | |
| MGMT methylation | 0.266 | ||
| Yes | 75.5 (80/106) | 24.5 (26/106) | |
| No | 66.7 (30/45) | 33.3 (15/45) | |
| IDH mutation | <0.001 | ||
| Yes | 77.2 (122/158) | 22.8 (36/158) | |
| No | 53.8 (43/80) | 46.3 (37/80) | |
| 1p/19q codeletion | 0.258 | ||
| Yes | 74.1 (63/85) | 25.9 (22/85) | |
| No | 67.1 (104/155) | 32.9 (51/155) | |
| Ki-67 | 0.020 | ||
| ≤5% | 74.3 (124/167) | 25.7 (43/167) | |
| >5% | 59.2 (42/71) | 40.8 (29/71) | |
| EGFRvIII nuclear translocation | <0.001 | ||
| <7% | 89.0 (129/145) | 11.0 (16/145) | |
| ≥7% | 40.0 (38/95) | 60.0 (57/95) | |